Dipraglurant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Dipraglurant
Dipraglurant.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C16H12FN3
Molar mass 265.285 g/mol
3D model (JSmol)

Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]

See also[edit]

References[edit]

  1. ^ a b Ana Martinez; Carmen Gil (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
  2. ^ John E. Macor (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
  3. ^ Susan H. Fox; Jonathan M. Brotchie (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
  4. ^ Addex Therapeutics. "Dipraglurant-ER for dystonia".

External links[edit]